Pharmaceutical Products: 70%
Health Products: 20%
Research and Development Services: 10%

Top 3 Markets:
China: 60%
USA: 20%
Europe: 10%

Sunshine Lake Pharma Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for 70% of total revenue. Health products and research and development services complement the portfolio with 20% and 10%, respectively.

The Chinese market is the most significant for the company, representing 60% of total revenue. The USA and Europe follow with 20% and 10%, highlighting Sunshine Lake Pharma's international presence and influence in these regions.

Production Sites: Guangdong, China (As of 2023)

Sunshine Lake Pharma Co., Ltd. mainly produces its pharmaceutical products in Guangdong, China. The company has modern production facilities there that cover the majority of its manufacturing capacities. This strategic location enables the company to benefit from proximity to key supply chains and markets in the region.

It is possible that the company will expand or diversify its production capacities in the coming years to respond to growing demand or regulatory requirements. Current information about new production sites or expansions should be regularly reviewed to consider the latest developments.

Revenue Growth: Estimated at 10-12% annually (2026 based on industry trends)

Research and Development Investments: Increased by 20% (2025)

Sunshine Lake Pharma Co., Ltd. is pursuing a growth strategy that heavily focuses on research and development. The company has increased its investments in this area by 20% to develop innovative drugs and expand its product pipeline.

Another key focus is on international expansion. The company plans to strengthen its presence in emerging markets to capitalize on the growing demand for high-quality pharmaceutical products.

In addition, Sunshine Lake Pharma is leveraging strategic partnerships and alliances with other pharmaceutical companies to facilitate access to new technologies and markets. This strategy is aimed at increasing revenue growth by 10-12% annually in the coming years.

Main raw materials: Active ingredients (APIs), excipients, packaging materials
Import countries: India, China, Germany

Sunshine Lake Pharma Co., Ltd. mainly imports active ingredients (APIs) that are essential for the production of their pharmaceutical products. India and China are the main suppliers as they are leading producers of APIs worldwide.

In addition, excipients and packaging materials are imported, with Germany being a significant supplier of high-quality pharmaceutical excipients and packaging solutions. These materials are crucial to ensure the quality and safety of the end products.

The company continuously optimizes its supply chains to reduce costs and ensure supply security.

Market Share: 8% in the Chinese generic drug market (2025)
R&D Expenses: 12% of revenue (2025)
Gross Margin: 45% (2025)

Sunshine Lake Pharma Co., Ltd. has a significant competitive advantage in the Chinese generic drug market, highlighted by an 8% market share. The company heavily invests in research and development, accounting for 12% of its revenue. These investments enable the company to develop innovative generics and differentiate itself from the competition.

The 45% gross margin indicates that Sunshine Lake Pharma is able to efficiently produce and distribute its products, reflecting strong operational efficiency. Together, these factors give the company a solid competitive edge in a fiercely competitive market.

Institutional Investor Share: 45% (estimated, 2026)
Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Sunshine Lake Pharma Co., Ltd. is estimated to be around 45%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and trust in the company.

In 2025, there were no significant insider buys or sells, which could indicate that the management and other insiders are satisfied with the current company strategy and valuation. This can also be seen as a sign of stable internal confidence in the company's future development.

Market share of Sunshine Lake Pharma Co., Ltd.: 4.5% (estimated for 2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 12.0%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 9.5%
3. China Resources Pharmaceutical Group Ltd.: 8.0%
4. CSPC Pharmaceutical Group Ltd.: 7.0%
5. Hengrui Medicine Co., Ltd.: 6.5%
6. Sunshine Lake Pharma Co., Ltd.: 4.5%
7. Livzon Pharmaceutical Group Inc.: 4.0%
8. Fosun Pharma: 3.5%
9. Yunnan Baiyao Group Co., Ltd.: 3.0%
10. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.: 2.5%

Moat of Sunshine Lake Pharma Co., Ltd.:

Sunshine Lake Pharma Co., Ltd. has a moderate moat, mainly supported by specialized product lines and strategic partnerships. Their focus on research and development, as well as the introduction of innovative pharmaceutical products, provides them with a certain advantage.

Compared to leading companies like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a broader product range, the moat of Sunshine Lake Pharma is less pronounced. These competitors have a stronger competitive advantage due to their size and market presence.

In summary, Sunshine Lake Pharma operates in a highly competitive market where the largest companies dominate through their comprehensive resources and networks. To strengthen their moat, Sunshine Lake Pharma could invest in strategic alliances and expanding their product range.

Revenue Growth: 8.5% (2025) Research and Development Expenses: 12% of revenue (2025) Market Share in the Asian Region: 5% (2025)

Sunshine Lake Pharma Co., Ltd. recorded a revenue growth of 8.5% in 2025. This indicates a solid business development supported by strong demand for their products. The company is heavily investing in research and development, with 12% of revenue allocated to this area. This demonstrates a commitment to innovation and the development of new products, which can lead to long-term competitive advantages.

The 5% market share in the Asian region shows that Sunshine Lake Pharma is well positioned in an important growth market. This could lead to further growth potential in the coming years, especially if the company expands its presence in other international markets.

Overall, the financial and strategic positioning of the company suggests that Sunshine Lake Pharma Co., Ltd. could be an attractive investment opportunity for investors interested in long-term growth.

Dividend payment: No dividend (as of 2026)

Sunshine Lake Pharma Co., Ltd. has not paid any dividends in recent years. The company is strongly focused on reinvesting profits into research and development as well as expanding into new markets.

The reliability of dividend payments is therefore not relevant as the company currently does not have a dividend policy. Investors should focus on the potential for capital growth and the company's strategic direction.